Conduit Pharmaceuticals Inc. (CDT)
NASDAQ: CDT · Real-Time Price · USD
0.4092
+0.0092 (2.30%)
At close: May 12, 2025, 4:00 PM
0.3959
-0.0133 (-3.25%)
After-hours: May 12, 2025, 7:34 PM EDT
Conduit Pharmaceuticals Employees
Conduit Pharmaceuticals had 6 employees as of December 31, 2024. The number of employees decreased by 1 or -14.29% compared to the previous year.
Employees
6
Change (1Y)
-1
Growth (1Y)
-14.29%
Revenue / Employee
n/a
Profits / Employee
-$2,967,000
Market Cap
4.64M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6 | -1 | -14.29% |
| Dec 31, 2023 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CDT News
- 3 days ago - Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases - GlobeNewsWire
- 4 days ago - Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset - GlobeNewsWire
- 26 days ago - Conduit Pharmaceuticals Announces Leadership Changes - GlobeNewsWire
- 4 weeks ago - Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects - GlobeNewsWire
- 6 weeks ago - Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases - GlobeNewsWire
- 7 weeks ago - Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904 - GlobeNewsWire
- 2 months ago - Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel - GlobeNewsWire
- 2 months ago - Conduit Progresses Phase II of its AI Initiative with Sarborg - GlobeNewsWire